

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Bayzed Health Group Inc**  
**佰澤醫療集團**

*(Incorporated under the laws of the Cayman Islands with limited liability)*  
**(Stock Code: 2609)**

**DISCLOSEABLE TRANSACTION IN RELATION TO  
PROVISION OF LOAN AND CORPORATE GUARANTEES  
TO HUANGSHAN SHOUKANG HOSPITAL**

**GRANT OF LOAN AND PROVISION OF CORPORATE GUARANTEES**

As disclosed in the prospectus of the Company dated June 13, 2025, under the Hospital Management Agreement between Huangshan Shoukang Hospital and Anhui Shoukang Investment, a non-wholly owned subsidiary of the Company, the Company will provide financial assistance to Huangshan Shoukang Hospital from time to time, including the grant of Loan and acting as its Corporate Guarantee for its Credit Facilities. The total loan balance for a Class III Hospital like Huangshan Shoukang Hospital shall not exceed RMB200.0 million at any time.

As at the date of this announcement, the balance of loan provided by the Group and corporate guarantees provided by the Group to Huangshan Shoukang Hospital is in aggregate approximately RMB188.0 million, which did not exceed the limit of RMB200.0 million as stated in the prospectus of the Company dated June 13, 2025.

The principal terms and conditions of the Loan and Guarantee Agreements are set out in the paragraphs headed “Principal Terms of the Loan” and “Principal Terms of the Guarantee Agreements” in this announcement. The Directors consider that the Loan and Guarantee Agreements and their terms are on normal commercial terms, fair and reasonable and are in the interests of the Company and its Shareholders as a whole.

## **LISTING RULES IMPLICATIONS**

According to Rule 14.22 of the Listing Rules, the Stock Exchange will aggregate a series of transactions and treat them as if there were one transaction if they are all completed within a 12-month period or are otherwise related. Since the grant of the Loan and the transactions contemplated under the Guarantee Agreements constitute financial assistance provided by the Group to Huangshan Shoukang Hospital, the Loan and the transactions contemplated under the Guarantee Agreements are required to be aggregated pursuant to Rule 14.22 of the Listing Rules.

As the borrower of the Loan, Huangshan Shoukang Hospital is the same as that under the Credit Facilities which was entered into with the Banks completed within 12 months prior to the date of this announcement, the transactions under the Loan and the Credit Facilities shall be aggregated as a series of transactions under Rule 14.22 of the Listing Rules.

As the highest applicable percentage ratio in respect of the transactions contemplated under the Guarantee Agreements, when aggregated with the Loan, is more than 5% but less than 25%, since 31 July 2025, the transactions contemplated under the Guarantee Agreements constitute a discloseable transaction for the Company and are therefore subject to the reporting and announcement requirements under Chapter 14 of the Listing Rules but are exempt from the circular and Shareholders' approval requirements under Chapter 14 of the Listing Rules.

In addition, as the assets ratio as defined under Rule 14.07(1) of the Listing Rules in respect of the transactions contemplated under the Guarantee Agreements when aggregated with the Loan exceeds 8%, the transactions contemplated under the Guarantee Agreements and the Loan will together give rise to a general disclosure obligation of the Company under Rules 13.13 and 13.15 of the Listing Rules. Relevant disclosures pursuant to Rules 13.13 and 13.15 of the Listing Rules are made in this announcement.

## **BACKGROUND**

As disclosed in the prospectus of the Company dated June 13, 2025, from time to time and as part of the Group's ordinary business, the Group, through Anhui Shoukang Investment, continues to provide loan and corporate guarantees in favour of Huangshan Shoukang Hospital, and such provision of financial assistance was conducted under the terms of the Hospital Management Agreement.

As at the date of this announcement, the balance of loan provided by the Group and corporate guarantees provided by the Group to Huangshan Shoukang Hospital is in aggregate approximately RMB188.0 million, which did not exceed the limit of RMB200.0 million as stated in the prospectus of the Company dated June 13, 2025.

## **PRINCIPAL TERMS IN RELATION TO THE LOAN**

The principal terms of the Loan are set out below:

|  |   |
|--|---|
| <b>Date:</b>   | December 31, 2021   |
| <b>Parties:</b>  | (i) the Lender (a non-wholly owned subsidiary of the Company) as lender; and<br><br>(ii) Huangshan Shoukang Hospital as borrower.               |
| <b>Maximum amount of the Loan and Corporate Guarantee:</b> | RMB200.0 million  |
| <b>Interest rate:</b>                                      | Non-interest bearing  |
| <b>Repayment Date:</b>                                     | Repayment on demand   |
| <b>Security:</b>   | Non-secured   |
| <b>Permitted use of the Loan:</b>                          | Unless with the Lender's prior written consent, Huangshan Shoukang Hospital shall only use the principal amount for hospital operation purpose. |

The Directors have approved the transactions contemplated under the Loan and confirmed that the terms thereof are fair and reasonable and in the interests of the Company and the Shareholders as a whole.

## **SOURCE OF FUNDING OF THE LOAN**

The source of funding of the Loan is the internal resources of the Group.

## **BASIS OF THE AMOUNT OF THE LOAN**

The amount of the Loan has been negotiated based on the actual financing needs of Huangshan Shoukang Hospital, with reference to the fee quotes obtained from external suppliers by Huangshan Shoukang Hospital to meet its capital demands for daily operation, procurement of pharmaceuticals and medical instruments and staff cost, etc.

## **PRINCIPAL TERMS OF THE GUARANTEE AGREEMENTS**

The principal terms of the Guarantee Agreements are summarised as follows:

### **Guarantee Agreement A**

**Date:** October 27, 2022

**Parties:** (i) Guarantor A  
(ii) Bank A

**Scope of guarantee:** the Company agreed to provide a corporate guarantee in favour of Bank A in respect of the Repayment Obligations (up to a maximum outstanding principal amount of RMB130.0 million), together with any interest (including but not limited to penalty interest and compound interest), default payment, liquidated damages and other relevant expenses reasonably incurred for the enforcement of the Bank A's rights in relation to the Repayment Obligations.

**Availability period:** From October 27, 2022 to October 27, 2027

### **Guarantee Agreement B**

**Date:** May 26, 2023

**Parties:** (i) Guarantor A  
(ii) Bank B

**Scope of guarantee:** the Company agreed to provide a corporate guarantee in favour of Bank B in respect of the Repayment Obligations (up to a maximum outstanding principal amount of RMB9.0 million), together with any interest (including penalty interest and compound interest), default payment, liquidated damages, transaction fees, difference of exchange rates, and other relevant expenses reasonably incurred for the enforcement of the Bank B's rights in relation to the Repayment Obligations.

**Availability period:** From May 26, 2023 to May 25, 2029

### **Guarantee Agreement C**

**Date:** January 30, 2024

**Parties:**

- (i) Guarantor A
- (ii) Guarantor B
- (iii) Bank C

**Scope of guarantee:** the Company agreed to provide a corporate guarantee in favour of Bank C in respect of the Repayment Obligations (up to a maximum outstanding principal amount of RMB10.0 million), together with any interest (including penalty interest), default payment, liquidated damages and other relevant expenses reasonably incurred for the enforcement of the Bank C's rights in relation to the Repayment Obligations.

**Availability period:** From January 30, 2024 to January 30, 2027

### **Guarantee Agreement D**

**Date:** May 19, 2024

**Parties:**

- (i) Guarantor A
- (ii) Guarantor B
- (iii) Bank D

**Scope of guarantee:** the Company agreed to provide a corporate guarantee in favour of Bank D in respect of the Repayment Obligations (up to a maximum outstanding principal amount of RMB30.0 million), together with any interest (including penalty interest), default payment, liquidated damages and other relevant expenses reasonably incurred for the enforcement of the Bank D's rights in relation to the Repayment Obligations.

**Availability period:** From May 19, 2024 to May 19, 2027

### **Guarantee Agreement E**

**Date:** March 27, 2025

**Parties:** (i) Guarantor A  
(ii) Bank C

**Scope of guarantee:** the Company agreed to provide a corporate guarantee in favour of Bank C in respect of the Repayment Obligations (up to a maximum outstanding principal amount of RMB17.0 million), together with any interest (including penalty interest), default payment, liquidated damages and other relevant expenses reasonably incurred for the enforcement of the Bank C's rights in relation to the Repayment Obligations.

**Availability period:** From March 27, 2025 to March 27, 2028

### **Guarantee Agreement F**

**Date:** April 23, 2025

**Parties:** (i) Guarantor A  
(ii) Bank E

**Scope of guarantee:** the Company agreed to provide a corporate guarantee in favour of Bank E in respect of the Repayment Obligations (up to a maximum outstanding principal amount of RMB10.0 million), together with any interest (including statutory interest, contractual interest, penalty interest, compound interest), default payment, liquidated damages and other relevant expenses reasonably incurred for the enforcement of the Bank E's rights in relation to the Repayment Obligations.

**Availability period:** From April 23, 2025 to April 23, 2028

## **Guarantee Agreement G**

**Date:** December 22, 2025

**Parties:** (i) Guarantor A  
(ii) Bank F

**Scope of guarantee:** the Company agreed to provide a corporate guarantee in favour of Bank F in respect of the Repayment Obligations (up to a maximum outstanding principal amount of RMB45 million), together with any interest (including but not limited to penalty interest and compound interest), default payment, liquidated damages, litigation cost, legal expenses and other relevant expenses reasonably incurred for the enforcement of the Bank F's rights in relation to the Repayment Obligations.

**Availability period:** From December 22, 2025 to December 22, 2026

## **Guarantee Agreement H**

**Date:** March 16, 2026

**Parties:** (i) Guarantor A  
(ii) Bank G

**Scope of guarantee:** the Company agreed to provide a corporate guarantee in favour of Bank G in respect of the Repayment Obligations (up to a maximum outstanding principal amount of RMB24.8 million), together with any interest (including penalty interest and compound interest), default payment, liquidated damages and other relevant expenses reasonably incurred for the enforcement of the Bank's rights in relation to the Repayment Obligations.

**Availability period:** From March 16, 2026 to March 16, 2027

## **SOURCE OF FUNDING OF THE CORPORATE GUARANTEES**

In the event that the Company becomes liable to pay to the Banks under the Guarantee Agreements, the Company intends to fund such payment through the internal resources of the Group.

## **INFORMATION ON THE LENDER, THE GROUP, HUANGSHAN SHOUKANG HOSPITAL AND THE BANKS**

### **Guarantor A**

Bayzed Medical Investment was incorporated in the PRC with limited liability and is a wholly-owned subsidiary of our Company. Bayzed Medical Investment principally engages in investment business in the PRC.

### **The Lender and Guarantor B**

Anhui Shoukang Investment was incorporated in the PRC with limited liability and is indirectly owned as to 69.92% by the Company. Anhui Shoukang Investment principally engages in hospital management business in the PRC.

### **The Group**

The Company was incorporated in the Cayman Islands as an exempted company with limited liability, the shares of which have been listed on the Stock Exchange since June 23, 2025. The Group principally engages in hospital management business and general hospital business in the PRC.

### **Huangshan Shoukang Hospital**

Huangshan Shoukang Hospital, located in Huangshan of Anhui Province, is a private not-for-profit Class III comprehensive private hospital (as defined in the prospectus of the Company dated June 13, 2025), which provides a full spectrum of general healthcare services with 36 clinical and medical technical departments, primarily including general surgery, paediatrics, obstetrics and gynecology, medical oncology, rehabilitation and orthopedics. Huangshan Shoukang Hospital is managed by Anhui Shoukang Investment, which is a non-wholly owned subsidiary of the Company, under Hospital Management Agreement.

As of the Latest Practicable Date, Anhui Shoukang Investment is the 100% investor of Huangshan Shoukang Hospital. The shareholders of Anhui Shoukang Investment are Anhui Baihui Hospital Management Company Limited (a wholly-owned subsidiary of the Company), Xu Jianping (徐建平) (the chairman of Anhui Shoukang Investment) and Xu Youfen (許友芬)

(the director of Anhui Ruizhong and Huangshan Bohong), holding approximately 67.9%, 23.0% and 1.2% of equity interests, respectively, and five limited partnerships, as the implementation platform of the employee stock incentive scheme, holding a total of 8.00% of the equity interests.

Huangshan Shoukang Hospital, as a not-for-profit hospital, is different from for-profit hospitals. The investor of Huangshan Shoukang Hospital is not entitled to any rights to dividend or the remaining assets after liquidation available under the laws and regulations of the PRC. As such, the concept of “ultimate beneficial owner” is not applicable given Huangshan Shoukang Hospital’s nature as a not-for-profit hospital.

To the best of the Directors’ knowledge, information and belief having made all reasonable inquiries, Huangshan Shoukang Hospital is a third party independent of the Company and connected persons of the Company.

### **The Banks**

To the best of the Directors’ knowledge, information and belief, having made all reasonable inquiries, the Banks are financial institutions established in the PRC and are principally engaged in, among others, the provision of banking business in the PRC; and each of the Banks and its ultimate beneficial owner(s) is a third party independent of the Company and connected persons of the Company.

### **REASONS FOR AND BENEFITS OF PROVISION OF LOAN AND CORPORATE GUARANTEES**

Under the Hospital Management Agreement, the Company is responsible to provide financial support and financing advice to Huangshan Shoukang Hospital. Since Huangshan Shoukang Hospital is a hospital managed by the Group, which pays a fixed percentage (i.e. 10.0%) of its revenue as management fees to the Group, assisting Huangshan Shoukang Hospital to maintain its operational capability and stability will also benefit and stabilize the source of income of the Group. Accordingly, the grant of the Loan to Huangshan Shoukang Hospital and provision of the Corporate Guarantees in favor of the Banks are both commercially and operationally beneficial to Huangshan Shoukang Hospital and the Group.

The Group has made the decision not to charge any interest to the Loan and fee from providing the Corporate Guarantees to Huangshan Shoukang Hospital in consideration of the contractual relationship between the Group and Huangshan Shoukang Hospital as well as the overall interests of the Group.

Further, the grant of the Corporate Guarantees by the Group should be considered in light of the credit risk of Huangshan Shoukang Hospital associated with the Repayment Obligations as the Company will only incur liabilities upon a call on the Corporate Guarantees arising from an event of default of Huangshan Shoukang Hospital on the Repayment Obligations. The Company has been closely monitoring the business and financial conditions of Huangshan Shoukang Hospital by reviewing its periodic financial reports and other information in connection with its business operation and is not aware of any material risks that Huangshan Shoukang Hospital may breach the Repayment Obligations. Based on the information currently available to the Company and barring unforeseen circumstances, the Directors are of the view that the probability of an event of default of Huangshan Shoukang Hospital is remote.

Having considered the above reasons, the Directors consider that the Guarantee Agreements and the transactions contemplated thereunder are on normal commercial terms, fair and reasonable and are in the interests of the Company and its Shareholders as a whole.

None of the Directors is considered to have a material interest in the Guarantee Agreements and the transactions contemplated thereunder, and therefore none of the Directors is required to abstain from voting on the relevant board resolutions approving the Guarantee Agreements and the transactions contemplated thereunder.

## **LISTING RULES IMPLICATIONS**

According to Rule 14.22 of the Listing Rules, the Stock Exchange will aggregate a series of transactions and treat them as if there were one transaction if they are all completed within a 12-month period or are otherwise related. Since the grant of the Loan and the transactions contemplated under the Guarantee Agreements constitute financial assistance provided by the Group to Huangshan Shoukang Hospital, the Loan and the transactions contemplated under the Guarantee Agreements are required to be aggregated pursuant to Rule 14.22 of the Listing Rules.

As the borrower of the Loan, Huangshan Shoukang Hospital is the same as that under the Credit Facilities which was entered into with the Banks completed within 12 months prior to the date of this announcement, the transactions under the Loan and the Credit Facilities shall be aggregated as a series of transactions under Rule 14.22 of the Listing Rules.

As the highest applicable percentage ratio in respect of the transactions contemplated under the Guarantee Agreements, when aggregated with the Loan, is more than 5% but less than 25%, since 31 July 2025, the transactions contemplated under the Guarantee Agreements constitute a discloseable transaction for the Company and are therefore subject to the reporting and announcement requirements under Chapter 14 of the Listing Rules but are exempt from the circular and Shareholders' approval requirement under Chapter 14 of the Listing Rules.

In addition, as the assets ratio as defined under Rule 14.07(1) of the Listing Rules in respect of the transactions contemplated under the Guarantee Agreements when aggregated with the Loan exceeds 8%, the transactions contemplated under the Guarantee Agreements and the Loan will together give rise to a general disclosure obligation of the Company under Rules 13.13 and 13.15 of the Listing Rules. Relevant disclosures pursuant to Rules 13.13 and 13.15 of the Listing Rules are made in this announcement.

## **REMEDIAL ACTIONS TO BE TAKEN BY THE COMPANY**

The Company deeply regrets its non-compliance with the Listing Rules (the “**Non-compliance**”) but the Company would like to stress that the Non-compliance was inadvertent and the Company had no intention to withhold any information relating to the Loan Agreement or Provision of Corporate Guarantee from disclosure and/or Shareholders’ approval. The Non-compliance was due to the careless omission and misunderstanding of the Listing Rules in respect of the aggregation of transactions under Rule 14.22 of the Listing Rules in the case of financial assistance provided by the Group to Huangshan Shoukang Hospital.

In order to prevent the occurrence of similar incidents and ensure compliance with the relevant requirements of the Listing Rules in the future, the Company has adopted/will adopt the following measures to enhance its internal control:

- (1) an internal memo has been issued to all Directors and department heads of the Group that the notifiable transaction requirements under Chapter 14 of the Listing Rules, in particular relating to the financial assistance provided by the Group to Huangshan Shoukang Hospital, must be strictly complied with and they shall keep the Company informed of any transactions which may involve disclosure and/or Shareholders’ approval requirements under Chapter 14 of the Listing Rules;
- (2) relevant internal training sessions in respect of Chapter 14 of the Listing Rules will be arranged for all Directors, department heads of the Group and relevant personnel of the Group before April 30, 2026 so as to update and refresh their knowledge and understanding on the requirements of the Listing Rules; and
- (3) enhancing the Group’s internal control system by, among other things, (i) adopted and implemented internal monitoring policies on the financial assistance provided by the Group to Huangshan Shoukang Hospital; and (ii) monitor the upper limit on the financial assistance provided by the Group to Huangshan Shoukang Hospital, i.e. the total loan balances shall not exceed RMB200.0 million at any time in respect of Class-III hospital (as disclosed in the “Financial Information” section of the prospectus dated June 13, 2025).

## DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions have the following meanings:

|                             |  |
|-----------------------------|--|
| “Anhui Ruizhong”            | Anhui Ruizhong Medical Technology Company Limited* (安徽省瑞眾醫療科技有限責任公司), a company established in the PRC with limited liability on December 31, 2020, a non-wholly-owned subsidiary of the Company   |
| “Anhui Shoukang Investment” | Anhui Shoukang Medical Investment Company Limited* (安徽首康醫療投資有限公司), a company established in the PRC with limited liability on December 19, 2014, a non-wholly owned subsidiary of our Company, which provides supervision and management services to Huangshan Shoukang Hospital |
| “Bank A”                    | China Construction Bank, Huangshan High Technology Industrial Development Zone Branch* (中國建設銀行股份有限公司黃山高新技術產業開發區支行)   |
| “Bank B”                    | Postal Savings Bank of China, Xiuning Province Branch (中國郵政儲蓄銀行股份有限公司休寧縣支行)  |
| “Bank C”                    | Huangshan Tunxi Rural Commercial Bank Co., Ltd., Likang Branch* (黃山屯溪農村商業銀行股份有限公司黎康支行)   |
| “Bank D”                    | Anhui Shexian Rural Commercial Bank Co., Ltd.* (安徽歙縣農村商業銀行股份有限公司)  |
| “Bank E”                    | Shanghai Pudong Development Bank Co. Ltd., Hefei Branch* (上海浦東發展銀行股份有限公司合肥分行)  |
| “Bank F”                    | Beijing Zhongguancun Bank Co., Ltd.* (北京中關村銀行股份有限公司)   |
| “Bank G”                    | Bank of Jiujiang, Hefei Yaohai Branch* (九江銀行股份有限公司合肥瑤海支行)  |
| “Banks”                     | Bank A, Bank B, Bank C, Bank D, Bank E, Bank F and Bank G  |

|                             |   |
|-----------------------------|---|
| “Bayzed Medical Investment” | Bayzed Medical Investment Group Company Limited* (佰澤醫療投資集團有限公司), a company established in the PRC with limited liability on July 31, 2017, a wholly-owned subsidiary of our Company   |
| “Board”                     | the board of directors of the Company   |
| “Business Day”              | a day other than a Saturday, Sunday or public holiday in the PRC  |
| “Credit Facilities”         | credit facilities granted by the Banks granted to Huangshan Shoukang Hospital which the Group issued guarantees to the Banks  |
| “Class-III hospital”        | the largest and best regional hospitals in China designated as Class-III hospitals by the NHC hospital classification system, typically having more than 500 beds, as for a comprehensive hospital providing high quality professional healthcare services covering a wide geographic area and undertaking higher academic and scientific research initiatives. The Class-III hospitals are graded into three sub-levels (A, B and C) based on the assessment of competent authorities and Class-IIIA hospitals are the highest ranking hospitals among Class-III hospitals |
| “Company”                   | Bayzed Health Group Inc, a company incorporated in the Cayman Islands with limited liability, the issued shares of which are listed on the Main Board of the Stock Exchange (stock code: 2609)  |
| “Corporate Guarantees”      | the corporate guarantees given by the Group in favour of the Banks pursuant to the Guarantee Agreements   |
| “connected person(s)”       | has the meaning ascribed to it under the Listing Rules  |
| “Director(s)”               | the director(s) of the Company  |

- “Guarantee Agreement A” the guarantee agreement dated October 27, 2022 entered into between Guarantor A and Bank A, pursuant to which the Company agreed to provide a corporate guarantee in favour of Bank A in respect of the Repayment Obligations (up to a maximum outstanding principal amount of RMB130.0 million), together with any interest (including but not limited to penalty interest and compound interest), default payment, liquidated damages and other relevant expenses reasonably incurred for the enforcement of the Bank A’s rights in relation to the Repayment Obligations
- “Guarantee Agreement B” the guarantee agreement dated May 26, 2023 entered into between Guarantor A and Bank B, pursuant to which the Company agreed to provide a corporate guarantee in favour of Bank B in respect of the Repayment Obligations (up to a maximum outstanding principal amount of RMB9.0 million), together with any interest (including penalty interest and compound interest), default payment, liquidated damages, transaction fees, difference of exchange rates, and other relevant expenses reasonably incurred for the enforcement of Bank B’s rights in relation to the Repayment Obligations
- “Guarantee Agreement C” the guarantee agreement dated January 30, 2024 entered into between Guarantor A, Guarantor B and Bank C, pursuant to which the Company agreed to provide a corporate guarantee in favour of Bank C in respect of the Repayment Obligations (up to a maximum outstanding principal amount of RMB10.0 million), together with any interest (including penalty interest), default payment, liquidated damages and other relevant expenses reasonably incurred for the enforcement of Bank C’s rights in relation to the Repayment Obligations
- “Guarantee Agreement D” the guarantee agreement dated May 19, 2024 entered into between Guarantor A, Guarantor B and Bank D, pursuant to which the Company agreed to provide a corporate guarantee in favour of Bank D in respect of the Repayment Obligations (up to a maximum outstanding principal amount of RMB30.0 million), together with any interest (including penalty interest), default payment, liquidated damages and other relevant expenses reasonably incurred for the enforcement of Bank D’s rights in relation to the Repayment Obligations

- “Guarantee Agreement E” the guarantee agreement dated March 27, 2025 entered into between Guarantor A and Bank C, pursuant to which the Company agreed to provide a corporate guarantee in favour of Bank C in respect of the Repayment Obligations (up to a maximum outstanding principal amount of RMB17.0 million), together with any interest (including penalty interest), default payment, liquidated damages and other relevant expenses reasonably incurred for the enforcement of the Bank C’s rights in relation to the Repayment Obligations
- “Guarantee Agreement F” the guarantee agreement dated April 23, 2025 entered into between Guarantor A and Bank E, pursuant to which the Company agreed to provide a corporate guarantee in favour of Bank E in respect of the Repayment Obligations (up to a maximum outstanding principal amount of RMB10.0 million), together with any interest (including statutory interest, contractual interest, penalty interest, compound interest), default payment, liquidated damages and other relevant expenses reasonably incurred for the enforcement of the Bank E’s rights in relation to the Repayment Obligations
- “Guarantee Agreement G” the guarantee agreement dated December 22, 2025 entered into between Guarantor A and Bank F, pursuant to which the Company agreed to provide a corporate guarantee in favour of Bank F in respect of the Repayment Obligations (up to a maximum outstanding principal amount of RMB45.0 million), together with any interest (including but not limited to penalty interest and compound interest), default payment, liquidated damages, litigation cost, legal expenses and other relevant expenses reasonably incurred for the enforcement of the Bank F’s rights in relation to the Repayment Obligations
- “Guarantee Agreement H” the guarantee agreement dated March 16, 2026 entered into between Guarantor A and Bank G, pursuant to which the Company agreed to provide a corporate guarantee in favour of Bank G in respect of the Repayment Obligations (up to a maximum outstanding principal amount of RMB24.8 million), together with any interest (including penalty interest and compound interest), default payment, liquidated damages and other relevant expenses reasonably incurred for the enforcement of the Bank G’s rights in relation to the Repayment Obligations

|                                 |  |
|---------------------------------|--|
| “Guarantee Agreements”          | Guarantee Agreement A, Guarantee Agreement B, Guarantee Agreement C, Guarantee Agreement D, Guarantee Agreement E, Guarantee Agreement F, Guarantee Agreement G and Guarantee Agreement H    |
| “Guarantor A”                   | Bayzed Medical Investment  |
| “Guarantor B”                   | Anhui Shoukang Investment  |
| “Group”                         | the Company and its subsidiaries   |
| “Hong Kong”                     | Hong Kong Special Administrative Region of the PRC   |
| “Hospital Management Agreement” | the hospital management agreement dated 31 December 2021 between Anhui Shoukang Investment and Huangshan Shoukang Hospital   |
| “Huangshan Bohong”              | Huangshan Bohong Pharmaceutical Sales Company Limited* (黃山博宏醫藥銷售有限公司), a company established in the PRC with limited liability on May 24, 2018, a non-wholly-owned subsidiary of our Company |
| “Huangshan Shoukang Hospital”   | Huangshan Shoukang Hospital (黃山首康醫院)   |
| “Lender”                        | Anhui Shoukang Investment  |
| “Listing Rules”                 | the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited   |
| “Loan”                          | the loan granted by the Lender to Huangshan Shoukang Hospital pursuant to the Hospital Management Agreement as at the date of this Announcement  |
| “NHC”                           | The National Administration of Traditional Chinese Medicine (國家中醫藥管理局)   |
| “percentage ratio(s)”           | has the meaning ascribed to it under the Listing Rule  |
| “PRC”                           | the People’s Republic of China and for the purposes of this announcement, excludes Hong Kong, Taiwan and Macau Special Administrative Region of the PRC                                      |

|                         |   |
|-------------------------|---|
| “Repayment Obligations” | all the Repayment Obligations of Huangshan Shoukang Hospital under the credit facilities, loan agreements and other document(s) entered into or to be entered into by the Banks and Huangshan Shoukang Hospital |
| “RMB”                   | Renminbi, the lawful currency of the PRC  |
| “Shareholder(s)”        | shareholder(s) of the Company   |
| “Stock Exchange”        | The Stock Exchange of Hong Kong Limited   |
| “%”                     | per cent  |

By order of the Board  
**Bayzed Health Group Inc**  
 (佰澤醫療集團)  
**Dr. Chen Haoyang**  
*Chairman and Executive Director*

Hong Kong, March 27, 2026

*As at the date of this announcement, the Board comprises executive Directors of Dr. Chen Haoyang, Mr. Zhao Yongkai, Ms. Xu Xu, Mr. Lu Jizhong and Mr. Feng Yu; and independent non-executive Directors of Mr. Chan Hok Leung, Ms. Liu Shuang and Dr. Guo Wei.*